CYTK Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of -15814.98% compared to Cytokinetics, Inc.'s net margin of -82.06%. Cytokinetics, Inc.'s return on equity of -- beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Cytokinetics, Inc. has a consensus price target of $79.56, signalling upside risk potential of 19.56%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.43%. Given that Cytokinetics, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Cytokinetics, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Cytokinetics, Inc. has a beta of 0.584, which suggesting that the stock is 41.614% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Cytokinetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cytokinetics, Inc. quarterly revenues are $1.9M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Cytokinetics, Inc.'s net income of -$306.2M is lower than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Cytokinetics, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics, Inc. is 90.80x versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Jasper Therapeutics, Inc. has a net margin of -15814.98% compared to Cytokinetics, Inc.'s net margin of --. Cytokinetics, Inc.'s return on equity of -- beat Jasper Therapeutics, Inc.'s return on equity of -204.39%.

Cytokinetics, Inc. has a consensus price target of $79.56, signalling upside risk potential of 19.56%. On the other hand Jasper Therapeutics, Inc. has an analysts' consensus of $18.14 which suggests that it could grow by 999.57%. Given that Jasper Therapeutics, Inc. has higher upside potential than Cytokinetics, Inc., analysts believe Jasper Therapeutics, Inc. is more attractive than Cytokinetics, Inc..

Cytokinetics, Inc. has a beta of 0.584, which suggesting that the stock is 41.614% less volatile than S&P 500. In comparison Jasper Therapeutics, Inc. has a beta of 2.688, suggesting its more volatile than the S&P 500 by 168.779%.

Cytokinetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jasper Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics, Inc. pays -- of its earnings as a dividend. Jasper Therapeutics, Inc. pays out -- of its earnings as a dividend.

Cytokinetics, Inc. quarterly revenues are $1.9M, which are larger than Jasper Therapeutics, Inc. quarterly revenues of --. Cytokinetics, Inc.'s net income of -$306.2M is lower than Jasper Therapeutics, Inc.'s net income of -$18.7M. Notably, Cytokinetics, Inc.'s price-to-earnings ratio is -- while Jasper Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics, Inc. is 90.80x versus -- for Jasper Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lantheus Holdings, Inc. has a net margin of -15814.98% compared to Cytokinetics, Inc.'s net margin of 7.23%. Cytokinetics, Inc.'s return on equity of -- beat Lantheus Holdings, Inc.'s return on equity of 14.66%.

Cytokinetics, Inc. has a consensus price target of $79.56, signalling upside risk potential of 19.56%. On the other hand Lantheus Holdings, Inc. has an analysts' consensus of $80.93 which suggests that it could grow by 35.4%. Given that Lantheus Holdings, Inc. has higher upside potential than Cytokinetics, Inc., analysts believe Lantheus Holdings, Inc. is more attractive than Cytokinetics, Inc..

Cytokinetics, Inc. has a beta of 0.584, which suggesting that the stock is 41.614% less volatile than S&P 500. In comparison Lantheus Holdings, Inc. has a beta of -0.102, suggesting its less volatile than the S&P 500 by 110.17%.

Cytokinetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lantheus Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics, Inc. pays -- of its earnings as a dividend. Lantheus Holdings, Inc. pays out -- of its earnings as a dividend.

Cytokinetics, Inc. quarterly revenues are $1.9M, which are smaller than Lantheus Holdings, Inc. quarterly revenues of $384M. Cytokinetics, Inc.'s net income of -$306.2M is lower than Lantheus Holdings, Inc.'s net income of $27.8M. Notably, Cytokinetics, Inc.'s price-to-earnings ratio is -- while Lantheus Holdings, Inc.'s PE ratio is 25.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics, Inc. is 90.80x versus 2.73x for Lantheus Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -15814.98% compared to Cytokinetics, Inc.'s net margin of 21.32%. Cytokinetics, Inc.'s return on equity of -- beat Pfizer Inc.'s return on equity of 10.84%.

Cytokinetics, Inc. has a consensus price target of $79.56, signalling upside risk potential of 19.56%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Cytokinetics, Inc. has higher upside potential than Pfizer Inc., analysts believe Cytokinetics, Inc. is more attractive than Pfizer Inc..

Cytokinetics, Inc. has a beta of 0.584, which suggesting that the stock is 41.614% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Cytokinetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Cytokinetics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Cytokinetics, Inc. quarterly revenues are $1.9M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Cytokinetics, Inc.'s net income of -$306.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Cytokinetics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics, Inc. is 90.80x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.